Eschler Asset Management LLP Acquires 40,000 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

Eschler Asset Management LLP grew its holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 100.0% in the 4th quarter, Holdings Channel reports. The fund owned 80,000 shares of the company’s stock after purchasing an additional 40,000 shares during the quarter. Immunocore comprises 1.9% of Eschler Asset Management LLP’s portfolio, making the stock its 14th biggest holding. Eschler Asset Management LLP’s holdings in Immunocore were worth $2,777,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Leonteq Securities AG bought a new stake in shares of Immunocore in the fourth quarter valued at approximately $30,000. Harbour Investments Inc. boosted its position in shares of Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after acquiring an additional 388 shares during the period. Arax Advisory Partners boosted its position in shares of Immunocore by 302.9% in the fourth quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after acquiring an additional 1,042 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Immunocore by 37.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock valued at $74,000 after acquiring an additional 572 shares during the period. Finally, Osaic Holdings Inc. boosted its position in shares of Immunocore by 117.4% in the second quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock valued at $97,000 after acquiring an additional 1,700 shares during the period. 84.50% of the stock is owned by institutional investors.

Immunocore Stock Performance

Shares of NASDAQ IMCR opened at $28.96 on Friday. The business has a fifty day simple moving average of $29.61 and a 200 day simple moving average of $32.33. The company has a current ratio of 4.18, a quick ratio of 4.15 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -52.65 and a beta of 0.74. Immunocore Holdings PLC Sponsored ADR has a one year low of $27.56 and a one year high of $40.71.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.51. The business had revenue of $106.68 million during the quarter, compared to analyst estimates of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.Immunocore’s revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.10 earnings per share. Sell-side analysts expect that Immunocore Holdings PLC Sponsored ADR will post 0.06 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on IMCR shares. Needham & Company LLC increased their price objective on Immunocore from $71.00 to $75.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a research report on Tuesday, April 21st. Wall Street Zen raised Immunocore from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Jefferies Financial Group lowered Immunocore from a “buy” rating to a “hold” rating and cut their target price for the company from $48.00 to $33.00 in a research note on Monday, March 16th. Finally, Mizuho set a $38.00 target price on Immunocore in a research note on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.71.

Immunocore Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.